Oncotarget

Corrections:

Correction: Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin

PDF  |  How to cite

Oncotarget. 2022; 13:583-584. https://doi.org/10.18632/oncotarget.28109

Metrics: PDF 360 views  |   ?  

Sixian Liang1,*, Xun Peng2,*, Xiaoli Li1, Ping Yang1, Linhao Xie1, Yaochen Li3, Caiwen Du1 and Guojun Zhang3

1Department of Breast Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China
2Department of Radiotherapy, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China
3The Breast Center, Cancer Hospital of Shantou University Medical College, Shantou 515031, PR China
*These authors have contributed equally to this work

Published: April 01, 2022

Copyright: © 2022 Liang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: In Figure 4C, panel ‘o’ contains a partial accidental overlap of panel ‘e’. The corrected Figure 4, produced using the original data, is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2015; 6:1020–1030. DOI: https://doi.org/10.18632/oncotarget.2741

Figure 4

Figure 4: (C) Immunohistochemical staining of xenograft tumors for p53, Bax, Bcl-2 and caspase-3 (magnification = 40×).


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28109